Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358275 | 1.00 | MAPT (0.47) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL6829887 | 0.77 | MAPT (0.50) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL3726386 | 0.73 | CYP1A2 (0.54) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL11528737 | 0.73 | MAPT (0.50) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| Ethane SCHEMBL14127500 | 0.73 | CYP1A2 (0.48) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL112992 | 0.72 | CYP1A2 (0.52) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL31276141 | 0.72 | CYP1A2 (0.52) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL4592372 | 0.72 | CYP1A2 (0.52) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL1560417 | 0.72 | MAPT (0.54) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL73063 | 0.72 | HDAC3 (0.61) | MAPTKMT2ACYP2C19HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115477688-A | Preparation method of eptifibatide | 山西德元堂药业有限公司 | 2022-12-16 | — | — | CN | claimed |
| CN-118055782-A | Gel compositions, systems, and methods | 波士顿科学国际有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-115477688-A | Preparation method of eptifibatide | 山西德元堂药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115477688-A | Preparation method of eptifibatide | 山西德元堂药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-108383902-A | Insulin analog dimer | 印第安纳大学研究及科技有限公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104981251-B | Insulin analog dimers | 印第安纳大学研究及科技有限公司 | 2018-03-20 | — | — | CN | disclosed |
| CN-101980725-B | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA AS | 2013-06-12 | — | — | CN | disclosed |
| CN-101980725-A | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA AS | 2011-02-23 | — | — | CN | disclosed |
| US-20070275046-A1 | Noval Surfactants and Applications Thereof | TS PHARMA (FR) | 2007-11-29 | — | — | US | disclosed |
| EP-1513538-A4 | NOVEL METHODS FOR THE DELIVERY OF POLYNUCLEOTIDES TO CELLS | MIRUS BIO CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1456225-A2 | EXTENDED NATIVE CHEMICAL LIGATION OF THREE OR MORE PEPTIDE FRAGMENTS | Geneprot, Inc. (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003042235-A9 | EXTENDED NATIVE CHEMICAL LIGATION OF THREE OR MORE PEPTIDE FRAGMENTS | GENEPROT INC (CH) | 2004-07-29 | — | — | WO | disclosed |
| EP-1392718-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | Geneprot, Inc. (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20030235916-A1 | Novel methods for the delivery of polynucleotides to cells | ROCHE MADISON INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003106636-A2 | NOVEL METHODS FOR THE DELIVERY OF POLYNUCLEOTIDES TO CELLS | MIRUS CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003042235-A2 | EXTENDED NATIVE CHEMICAL LIGATION OF THREE OR MORE PEPTIDE FRAGMENTS | GENEPROT, INC. (CH) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002098902-A2 | IMPROVED NATIVE CHEMICAL LIGATION WITH THREE OR MORE COMPONENTS | GENEPROT, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| EP-1025118-A1 | SPACER PEPTIDES AND MEMBRANES CONTAINING SAME | MERCK PATENT GmbH (DE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020649-A1 | SPACER PEPTIDES AND MEMBRANES CONTAINING SAME | MERCK PATENT GMBH (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1995020404-A1 | TRIPLEX-FORMING PAIRED-ION OLIGONUCLEOTIDES AND METHODS FOR PREPARING AND USING SAME | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275046-A1 | Noval Surfactants and Applications Thereof | SGMS1, SGMS2, ANXA6 | MAPT 1080/4885KMT2A 4733/4885CYP2C19 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.